Canada markets closed

RepliCel Life Sciences Inc. (RP.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.11000.0000 (0.00%)
At close: 09:55AM EDT
Full screen
Previous Close0.1100
Open0.1300
Bid0.1050 x 0
Ask0.1350 x 0
Day's Range0.1100 - 0.1300
52 Week Range0.1100 - 0.4200
Volume24,000
Avg. Volume6,993
Market Cap4.702M
Beta (5Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.1160
Earnings DateNov 27, 2015 - Nov 30, 2015
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    RepliCel Announces Material Patent Milestones

    New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key marketsVANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, is pleased to announce the filing of a new patent application covering novel aspects of the De

  • ACCESSWIRE

    RepliCel Closed Final Tranche of Strategic Investment Commitment

    VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has closed the final tranche of the investment by MainPointe Pharmaceuticals ("MainPointe") as outlined in the share purchase agreement signed by the parties earlier this year.

  • ACCESSWIRE

    RepliCel Terminates License Agreement with Shiseido

    VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today that the dispute between Shiseido and RepliCel has led to the Company electing to terminate the license agreement with Shiseido.